Alvine Pharmaceuticals, Inc. Initiates Enrollment in Phase 2a Clinical Trial of ALV003 for Use in the Treatment of Celiac Disease

SAN CARLOS, Calif.--(BUSINESS WIRE)--Alvine Pharmaceuticals, Inc. today announced that patient enrollment has begun in a Phase 2a, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ALV003 for use in the treatment of celiac disease.

Back to news